|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
05.05.26 - 14:15
|
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes (GlobeNewswire EN)
|
|
|
MALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen”) (NASDAQ: OCGN) today announced the pricing of $115 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Ocugen also granted the initial purchaser of the notes a 13-day option to purchase up to an additional $15 million aggregate principal amount of the notes. The sale of the notes to the initial purchaser is expected to close on May 7, 2026, subject to customary closing conditions, and is expected to result in approximately $99.5 million (or approximately $112.6 million if the initial purchaser exercises its option to purchase additional notes in full) in net proceeds to Ocugen after deducting the initial purchaser's discount and estimated offering expenses payable by Ocugen....
|
|
|
04.05.26 - 22:06
|
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes (GlobeNewswire EN)
|
|
|
MALVERN, Pa., May 04, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced its intention to offer, subject to market conditions and other factors, $115 million aggregate principal amount of Convertible Senior Notes due 2034 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Ocugen also expects to grant the initial purchaser of the notes a 13-day option to purchase up to an additional $15 million aggregate principal amount of the notes. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering....
|
|
|
|
|
23.04.26 - 13:06
|
Ocugen to Present at April 2026 Investor and Industry Conferences (GlobeNewswire EN)
|
|
|
MALVERN, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at Oppenheimer's 3rd Annual Innovation on the Island Biotech Summit from April 27-29, 2026 in Rio Grande, Puerto Rico; and Abhi Gupta, MBA, Executive Vice President, Commercial and Business Development at Ocugen will present at the 2026 Cell & Gene Meeting on the Mediterranean being held April 28-30, 2026 in Rome, Italy....
|
|
|
|
|
|
|
|
|
10.04.26 - 15:57
|
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells (PR Newswire)
|
|
|
AVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related Disease Issued on behalf of Avaí Bio, Inc. Companies mentioned in this article: Avaí Bio, Inc. (OTCQB: AVAI), Lineage Cell Therapeutics, Inc. (NYSE American: LCTX), Ocugen, Inc. (NASDAQ: OCGN),......
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
